Clinical significance of <i>RETN</i> gene expression and rs3219175 G &gt; a polymorphism in cancer

The inflammatory cytokine resistin, which is encoded by the <i>RETN</i> gene, plays a variety of roles in cancer. This study aimed to assess the relationship between <i>RETN</i> gene expression and cancer stage, survival prognosis, immune infiltration, and drug sensitivity, and whether the rs3219175 G > A polymorphism affected the expression of the <i>RETN</i> gene and cancer risk. The clinical significance of <i>RETN</i> gene expression and the rs3219175 polymorphism in cancer was analyzed by the GSCA platform, GTEx database and STATA software. The results showed that <i>RETN</i> gene expression was associated with the stage of thyroid carcinoma, survival prognosis and immune infiltration of certain cancers, and sensitivity to multiple drugs. The rs3219175 polymorphism could influence the expression of the <i>RETN</i> gene in a wide range of tissues. Furthermore, <i>RETN</i> gene rs3219175 polymorphism was significantly associated with cancer risk [GA vs. GG: OR = 2.27, 95%CI = 1.26-4.09; (GA + AA) vs. GG: OR = 2.23, 95%CI = 1.28-3.88; A vs. G: OR = 1.72, 95%CI = 1.15-2.58]. In conclusion, the current study suggested that resistin might serve as a prognostic marker and therapeutic target for certain cancers, and the rs3219175 polymorphism might be used as a marker for predicting cancer risk.